• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS.

作者信息

Rösler Wiebke, Bink Andrea, Bissig Marina, Imbach Lukas, Marques Maggio Ewerton, Manz Markus G, Müller Thomas, Roth Patrick, Rushing Elisabeth, Widmer Corinne, Zenz Thorsten, von Moos Seraina, Müller Antonia M S

机构信息

Department of Medical Oncology and Hematology, University Hospital Zurich, Switzerland.

Department of Neuroradiology, University Hospital Zurich, Switzerland.

出版信息

Hemasphere. 2022 Jun 17;6(7):e733. doi: 10.1097/HS9.0000000000000733. eCollection 2022 Jul.

DOI:10.1097/HS9.0000000000000733
PMID:35747591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9208876/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9a/9208876/977ad072087b/hs9-6-e733-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9a/9208876/fa6ad502ba73/hs9-6-e733-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9a/9208876/977ad072087b/hs9-6-e733-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9a/9208876/fa6ad502ba73/hs9-6-e733-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c9a/9208876/977ad072087b/hs9-6-e733-g002.jpg

相似文献

1
CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS.检查点抑制后进行嵌合抗原受体T细胞输注可诱导中枢神经系统化疗难治性移植后淋巴细胞增生性疾病缓解。
Hemasphere. 2022 Jun 17;6(7):e733. doi: 10.1097/HS9.0000000000000733. eCollection 2022 Jul.
2
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain.嵌合抗原受体T细胞疗法对脑B细胞淋巴瘤有效，但效果不持久。
Front Oncol. 2020 Aug 4;10:1306. doi: 10.3389/fonc.2020.01306. eCollection 2020.
3
Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report.抗CD19嵌合抗原受体T细胞疗法治疗伴有11q畸变的难治性侵袭性伯基特样淋巴瘤后发生的肾移植T细胞介导的排斥反应：一例报告
Am J Kidney Dis. 2022 May;79(5):760-764. doi: 10.1053/j.ajkd.2021.07.012. Epub 2021 Aug 27.
4
CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review.实体器官移植受者发生移植后淋巴细胞增生性疾病的CAR-T治疗：病例报告及文献综述
Curr Res Transl Med. 2021 Oct;69(4):103304. doi: 10.1016/j.retram.2021.103304. Epub 2021 Jul 22.
5
Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases.输注爱泼斯坦-巴尔病毒特异性细胞毒性T淋巴细胞作为高危移植后淋巴细胞增生性疾病患者缓解后的治疗：两例报告。
Int J Hematol. 2018 May;107(5):596-603. doi: 10.1007/s12185-017-2381-3. Epub 2017 Nov 29.
6
Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review.抗CD19嵌合抗原受体T细胞联合程序性细胞死亡蛋白1抑制剂治疗难治性移植后淋巴细胞增生性疾病患者的安全性和有效性：病例报告及文献综述
Front Oncol. 2021 Sep 16;11:726134. doi: 10.3389/fonc.2021.726134. eCollection 2021.
7
Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法治疗心脏移植受者的移植后淋巴细胞增生性疾病（PTLD）
Pediatr Transplant. 2021 Aug;25(5):e13861. doi: 10.1111/petr.13861. Epub 2020 Oct 1.
8
Post-transplant indolent T cell lymphoproliferative disorder in living donor liver transplantation: a case report.活体肝移植术后惰性T细胞淋巴增殖性疾病：一例报告
Surg Case Rep. 2020 Jun 26;6(1):147. doi: 10.1186/s40792-020-00904-y.
9
Toxoplasmic Encephalitis Followed by Primary EBV-Associated Post-Transplant Lymphoproliferative Disorder of the Central Nervous System in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Report.患者在行异基因造血干细胞移植后发生弓形体脑炎和原发性 EBV 相关的中枢神经系统移植后淋巴组织增生性疾病：病例报告。
Transplant Proc. 2020 Nov;52(9):2858-2860. doi: 10.1016/j.transproceed.2020.08.002. Epub 2020 Aug 29.
10
PD-1 Blockade Aggravates Epstein-Barr Virus Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4 T Cell Dysregulations.程序性死亡蛋白1（PD-1）阻断加重人源化小鼠移植后EB病毒淋巴增殖性疾病，导致中枢神经系统受累和CD4 T细胞失调。
Front Oncol. 2021 Jan 12;10:614876. doi: 10.3389/fonc.2020.614876. eCollection 2020.

引用本文的文献

1
Case Report: subhepatic appendicitis complicated by hepatic abscess as the initial presentation of primary diffuse large B-cell lymphoma of the appendix: first reported case.病例报告：肝下阑尾炎合并肝脓肿作为阑尾原发性弥漫性大B细胞淋巴瘤的首发表现：首例报道病例
Front Oncol. 2025 Jun 16;15:1591905. doi: 10.3389/fonc.2025.1591905. eCollection 2025.
2
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.严重毒性，但在大B细胞淋巴瘤中免疫检查点抑制剂治疗后CAR T细胞长期持续存在。
Leuk Lymphoma. 2025 Mar;66(3):535-540. doi: 10.1080/10428194.2024.2430703. Epub 2024 Nov 20.
3

本文引用的文献

1
Successful Treatment of Pediatric Refractory Burkitt Lymphoma PTLD after Liver Transplantation using Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.抗 CD19 嵌合抗原受体 T 细胞疗法成功治疗肝移植后小儿难治性 Burkitt 淋巴瘤 PTLD。
Cell Transplant. 2021 Jan-Dec;30:963689721996649. doi: 10.1177/0963689721996649.
2
Safety of CAR T-cell therapy in kidney transplant recipients.肾移植受者中CAR T细胞疗法的安全性。
Blood. 2021 May 6;137(18):2558-2562. doi: 10.1182/blood.2020008759.
3
Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series.
Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb.
接受CAR-T细胞疗法患者的神经认知功能变化：艰难攀登之路。
Pharmaceuticals (Basel). 2024 May 6;17(5):591. doi: 10.3390/ph17050591.
4
Transplant Onconephrology: An Update.移植肿瘤肾脏病学：更新。
Semin Nephrol. 2022 Nov;42(6):151348. doi: 10.1016/j.semnephrol.2023.151348. Epub 2023 May 18.
5
Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers.人类调节性 T 细胞：了解 Tregs 在特定自身免疫性皮肤疾病和移植后非黑色素瘤皮肤癌中的作用。
Int J Mol Sci. 2023 Jan 12;24(2):1527. doi: 10.3390/ijms24021527.
6
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.嵌合抗原受体 T 细胞（CAR-T）疗法治疗实体器官移植受者：病例报告和系统评价。
Bone Marrow Transplant. 2023 Apr;58(4):353-359. doi: 10.1038/s41409-022-01907-z. Epub 2022 Dec 27.
抗 CD19 CAR-T 疗法治疗 EBV 阴性移植后淋巴组织增生性疾病：单中心病例系列。
Bone Marrow Transplant. 2021 May;56(5):1031-1037. doi: 10.1038/s41409-020-01145-1. Epub 2020 Nov 23.
4
CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder.嵌合抗原受体 T 细胞疗法治疗移植后难治性淋巴增殖性疾病的实体器官移植受者。
Am J Transplant. 2021 Feb;21(2):809-814. doi: 10.1111/ajt.16367. Epub 2020 Dec 5.
5
Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy.嵌合抗原受体T细胞疗法治疗心脏移植受者的移植后淋巴细胞增生性疾病（PTLD）
Pediatr Transplant. 2021 Aug;25(5):e13861. doi: 10.1111/petr.13861. Epub 2020 Oct 1.
6
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain.嵌合抗原受体T细胞疗法对脑B细胞淋巴瘤有效，但效果不持久。
Front Oncol. 2020 Aug 4;10:1306. doi: 10.3389/fonc.2020.01306. eCollection 2020.
7
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
8
CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma.CD19和CD70双靶点嵌合抗原受体T细胞疗法治疗复发难治性原发性中枢神经系统弥漫性大B细胞淋巴瘤
Front Oncol. 2019 Dec 4;9:1350. doi: 10.3389/fonc.2019.01350. eCollection 2019.
9
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.tisagenlecleucel CAR T 细胞疗法治疗中枢神经系统淋巴瘤。
Blood. 2019 Sep 12;134(11):860-866. doi: 10.1182/blood.2019001694. Epub 2019 Jul 18.
10
Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.原发性睾丸弥漫性大B细胞淋巴瘤伴中枢神经系统进展患者的嵌合抗原受体T细胞疗法成功案例。
Leuk Lymphoma. 2019 Nov;60(11):2814-2816. doi: 10.1080/10428194.2019.1605507. Epub 2019 May 14.